Recent research have focused on the convergence of GLP|GIP|glucagon receptor stimulant therapies and dopaminergic neurotransmission. While GLP activators are commonly employed for managing type 2 diabetes mellitus, their unexpected consequences on reinforcement circuits, specifically governed by dopaminergic systems, are attracting considerable … Read More